Eligard three-month injectable
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Three-month sustained-release Eligard (leuprolide acetate for injectable suspension) 22.5 mg receives FDA approval July 24 for the palliative treatment of advanced prostate cancer. Once-monthly 7.5 mg Eligard was approved Jan. 23 and launched in May. Physicians often start patients on a monthly leuprolide formulation and then switch responding patients to a 90- or 120-day product (Pharmaceutical Approvals Monthly, February 2002, p. 3